welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
Peak Cough Flow and Cough Clearance in Patients With Muscular Dystrophy
study id #: NCT02034305
condition: Duchenne Muscular Dystrophy
This study is to determine whether physiologic measures (peak cough flow, measures of respiratory muscle strength including MIP, MEP, SNIP, and spirometry) can predict spontaneous cough clearance (as measured by a nuclear medicine study) in children with neuromuscular disease. It will also determine whether airway clearance is augmented by high frequency chest wall oscillation.
mechanism of action: No pharmaceutical intervention
last updated: February 15, 2019
start date: January 2014
estimated completion: January 2020
size / enrollment: 15
- Spontaneous cough clearance [ Time Frame: Assessed at multiple time points over 30 minutes ]
• Age 6-21; able to cooperate with study procedures
• Duchenne Muscular Dystrophy OR Becker Muscular Dystrophy
• Need for mechanical ventilation during the day
• Recent (within 2 weeks) lower respiratory tract infection
A Phase 1b Study of SMT C1100 in Subjects With Duchenne Muscular Dystrophy (DMD)The purpose of this study is to determin...
A Phase I/II Study of BMN053 in Subjects With Duchenne Muscular Dystrophy (DMD)The purpose of the study is to see wheth...
Sarepta Announces Clinical Hold Lifted for its Duchenne Muscular Dystrophy Micro-dystrophin Gene Therapy ProgramSarepta Therapeutics, Inc., a commercial...
Capricor Therapeutics Announces Positive Results from its Interim Analysis in the HOPE-2 Trial to Treat Patients wit...Capricor Therapeutics, Inc. (NASDAQ: CAP...
A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study Assessing PK, Safety, Tolerability in Non-ambu...The purpose of this study is investigate...
Finding the Optimum Regimen for Duchenne Muscular DystrophyThe Finding the Optimum Regimen for Duch...
Treatment Effect of Tamoxifen on Patients With DMDDuchenne muscular dystrophy (DMD) is a p...
Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-infl...We report a first-in-patient study of va...
How Facebook and Twitter could be the next disruptive force in clinical trialsAmber Sapp was browsing the Internet lat...
MoveDMD: phase 2 trial of edasalonexent, an NF-κB inhibitor, in 4 to 7-year old patients with Duchenne muscular dys...NF-κB is activated from infancy in DMD,...